医学
无容量
危险系数
内科学
头颈部癌
头颈部鳞状细胞癌
埃罗替尼
随机对照试验
临床终点
化疗
癌症
肿瘤科
外科
胃肠病学
免疫疗法
置信区间
表皮生长因子受体
作者
Vijay Patil,Vanita Noronha,Nandini Menon,Rahul Rai,Atanu Bhattacharjee,Ajay Singh,Kavita Nawale,Shweta Jogdhankar,Rupali Tambe,Sachin Dhumal,Riddhi Sawant,Mitali Alone,Devanshi Karla,Zoya Peelay,Shruti Pathak,Arun Balaji,Suman Kumar,Nilendu Purandare,Archi Agarwal,Ameya Puranik
摘要
To our knowledge, this is the first-ever randomized study to demonstrate that the addition of low-dose nivolumab to metronomic chemotherapy improved OS and is an alternative standard of care for those who cannot access full-dose checkpoint inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Nole
张欢馨
cdercder
yjh123
OK
Kao
东方元语
woshi123
科研狗
ddd
aajhajkahna
xing_xing
Criminology34
行走的荷尔蒙
ming2026
OCDer
天晴
Moonpie
飞快的慕山
渡人舟
皖公网安备34019202002308
